Valuation: Annexon, Inc.

Market Cap 835M 726M 675M 620M 1.17B 79.69B 1.19B 7.96B 3.12B 39.67B 3.14B 3.07B 133B P/E 2026 *
-5.4x
P/E 2027 * -6.01x
Enterprise Value 740M 644M 599M 550M 1.04B 70.67B 1.05B 7.06B 2.77B 35.18B 2.78B 2.72B 118B EV / Sales 2026 *
-
EV / Sales 2027 * 13.4x
Free-Float
93.57%
Yield 2026 *
-
Yield 2027 * -
1 day-3.32%
1 week-2.39%
1 month-8.20%
3 months-11.39%
6 months-18.35%
Current year+1.49%
1 week 4.76
Extreme 4.76
5.4
1 month 4.76
Extreme 4.76
6.58
Current year 4.46
Extreme 4.46
7.18
1 year 2.03
Extreme 2.03
7.18
3 years 1.28
Extreme 1.285
8.4
5 years 1.28
Extreme 1.285
23.61
10 years 1.28
Extreme 1.285
38.01
Manager TitleAgeSince
Chief Executive Officer 58 30/11/2014
Director of Finance/CFO 53 31/05/2019
Chief Tech/Sci/R&D Officer 68 26/07/2023
Director TitleAgeSince
Director/Board Member 58 30/11/2014
Director/Board Member 65 30/11/2014
Director/Board Member 67 04/02/2021
Date Insider Type Main position Quantity % Market Cap.
19/02/26 Free

Chief Technology Officer

312,500 0.2159%
19/02/26 Free

Chief Executive Officer

1,250,000 0.8637%
19/02/26 Free

Executive/Senior Manager

312,500 0.2159%
Change 5-day change 1-year change 3-year change Capi.($)
-3.32%-2.39%+107.96%+43.93% 835M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.44%-3.65%+43.08%+143.72% 23.47B
Weighted average by Cap. +0.22%-2.96%+31.07%+116.58%

Financials

2026 *2027 *
Net sales - 40.38M 35.1M 32.67M 30M 56.65M 3.85B 57.53M 385M 151M 1.92B 152M 148M 6.43B
Net income -188M -164M -152M -140M -264M -17.99B -268M -1.8B -705M -8.96B -708M -692M -30.03B -191M -166M -154M -142M -268M -18.22B -272M -1.82B -714M -9.07B -717M -701M -30.42B
Net Debt -94.47M -82.12M -76.44M -70.18M -133M -9.02B -135M -901M -354M -4.49B -355M -347M -15.05B -292M -254M -236M -217M -409M -27.86B -416M -2.78B -1.09B -13.87B -1.1B -1.07B -46.52B
Logo Annexon, Inc.
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Employees
93
Date Price Change Volume
31/07/26 US$5.095 -3.32% 2,800,727
30/07/26 US$5.270 +8.44% 2,612,790
29/07/26 US$4.860 -2.21% 3,464,094
28/07/26 US$4.970 -3.12% 2,495,623
27/07/26 US$5.130 -1.72% 1,634,974
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
5.095USD
Average target price
13.25USD
Spread / Average Target
+160.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANNX Stock